Araris Biotech AG news

Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. Bernd Schlereth as Chief Development Officer (CDO). He brings with him more than 20 years of experience in pharmaceutical drug development.

Between 2019 and 2021 Dr. Bernd Schlereth worked as Vice President Oncology Research at Molecular Partners AG. From 2013 to 2019 he was employed at Janssen/Covagen AG as Senior Director Nonclinical Development and betw

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer.

“We are thrilled to welcome Filippo to our executive team,” said Philipp Spycher, Ph.D., chief executive officer of Araris Biotech. “Filippo’s extensive experience in identifying business development and licensing opportunities in the biotech space will be extrem

Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular Lymphoma Innovation. The round also included participation from existing

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect.

The presentation will highlight Araris’ proprietary linker technology, which enables the conjugation of various potent drug payloads to native “off-the-shelf” antibodies in a single step

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will present data on Araris’ linker technology at the 13th Annual World ADC Conference in San Diego. The poster presentation, titled, "Inducing complete and long-lasting tumor eradications of a nectin-4 ADC generated with a novel linker technology,” will be given on September 7, 2022, at 5:45 p.m. PT during the conference’s scientific poster